The modulatory effect of tranilast on neuropathic pain in type-2 diabetes (T2DM) remains unclear. We monitored interleukin (IL)-1β, nuclear factor-κB (NF-κB) and tumour necrosis factor-α (TNF-α) levels during the progression of T2DM induced neuropathic pain in rats, and assessed the impact of tranilast treatment of increasing concentrations (0, 200 and 400 mg/kg/day via oral gavage in 1% NaHCO3 delivered as 100 mg/kg twice a day) on the levels of cytokine production, as well as on...